Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 522 | 68 | 440 |
| Samples | 175 | 31 | 139 |
| Peptides | 163 | 28 | 134 |
Function
DCTN2 · Dynactin subunit 2
This gene encodes a 50-kD subunit of dynactin, a macromolecular complex consisting of 10-11 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein. It is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit is present in 4-5 copies per dynactin molecule. It contains three short alpha-helical coiled-coil domains that may mediate association with self or other dynactin subunits. It may interact directly with the largest subunit (p150) of dynactin and may affix p150 in place. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2012].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 133 amino-acid changes on canonical ENST00000548249 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DCTN2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DCTN2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Unknown | 0/10 0% | 1/29 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Burkitts Lymphoma | 2/32 6% | 2/196 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 4/612 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Bladder Carcinoma | 0/58 0% | 8/956 1% |
| Colorectal Carcinoma | 4/143 3% | 18/3239 1% |
| Other Solid Cancers | 1/94 1% | 8/1515 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 4/1390 0% |
| Melanoma | 1/210 0% | 10/1899 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Cervical Carcinoma | 1/35 3% | 1/422 0% |
| Other Blood Cancers | 0/61 0% | 12/2725 0% |
| Head and Neck Carcinoma | 2/85 2% | 5/1574 0% |
| Gastric Carcinoma | 0/74 0% | 8/1809 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Kidney Carcinoma | 1/85 1% | 6/1862 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 1/810 0% |
| Breast Carcinoma | 1/144 1% | 6/3264 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
Mutation Distribution
Where DCTN2 is mutated · all tissues, split by cell line vs tissue
How many mutations in DCTN2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 522 mutations in DCTN2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|